Systematic review of the efficacy of stereotactic ablative radiotherapy for oligoprogressive disease in metastatic cancer

CONCLUSIONS: SABR appears to have clinical benefit in oligoprogresssive prostate, lung, and renal patients. However, the optimal management of patients with oligoprogressive disease is still somewhat uncertain due to lack of prospective data. This will hopefully become clearer in the near future with the publication of further randomised trials.PMID:38648995 | DOI:10.1016/j.radonc.2024.110288
Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - Category: Radiology Authors: Source Type: research